ArticleBMC urology2025

Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma.

Tianxiang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.